• Kazia Therapeutics delayed its Form 20-F annual report for the year ended June 30, 2026, beyond the November 2, 2026 deadline.
• Filing is expected within 15 calendar days of the deadline.
• New accelerated-filer status triggered first-time Sarbanes-Oxley Section 404(b) requirements, requiring additional time to complete year-end reporting and internal-control assessments.
• Net loss is expected to widen from fiscal 2025, primarily reflecting higher operating expenses and non-cash fair value movements on financial liabilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-443609), on November 02, 2026, and is solely responsible for the information contained therein.